Impressive results from phase 3 RCT of the microtubule inhibitor Sabizabulin vs placebo in high risk COVID inpatients on O2. Compared to placebo, S

Impressive results from phase 3 RCT of the microtubule inhibitor Sabizabulin vs placebo in high risk COVID inpatients on O2. Compared to placebo, S